Clinically researched live cultures for Candida
Proprietary and patented strain of Saccharomyces cerevisiae CNCM I-3856 with proven efficacy to: limit Candida albicans proliferation and inhibit it becoming pathogenic; reduce inflammation, protect the vaginal epithelium, bind and clear C. albicans, inhibit Gardnerella vaginalis and prevent vaginal infections.
This strain of S. cerevisiae has been used in human clinical trials in which it significantly controlled C. albicans proliferation and decreased the risk of recurrence by 54% compared to placebo.
Key Benefits
Clinically researched for its effects on C. albicans (thrush) and G. vaginalis (BV)
S. cerevisiae CNCM I-3856 has been researched for its effect on pathogens associated with candida (thrush)
Supports a normal Oral, Gut and Vaginal Microbiome
S. cerevisiae CNCM I-3856 has been shown in studies to support normal multiple microbiomes